Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2025-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion (which is 'Appropriate' or 'Unqualified'), key financial data, and confirms the receipt of the audit report from the external auditor (Samil PwC). While it contains financial data, it is a standard regulatory disclosure announcement regarding the submission of the audit report rather than the full annual report (10-K) or a standalone audit report document. Therefore, it fits the 'Report Publication Announcement' (RPA) category as it announces the filing of the audit report. FY 2024
2025-03-18 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Eubiologics Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typically found in a full 10-K, focusing specifically on the audit and financial statements. FY 2024
2025-03-18 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) regarding a previously filed 'Notice of General Meeting of Shareholders' (주주총회소집공고). It specifically details corrections to the financial statements (재무제표) that were originally included in the meeting notice, such as the balance sheet, income statement, and cash flow statement, due to adjustments from external audit results. Since this document is part of the materials provided for an Annual General Meeting (AGM) and contains the updated financial information for that meeting, it is classified as AGM Information.
2025-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Eubiologics. It contains the meeting agenda, date, location, and details regarding voting procedures, director appointments, and financial statement approval. This document is a formal notice sent to shareholders to solicit their participation and votes for the upcoming AGM. According to the provided definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2025-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) for the 15th Annual General Meeting of Shareholders of Eubiologics Co., Ltd. It contains detailed information regarding the meeting agenda, voting procedures (electronic voting/proxy), and the company's business status, which is standard for a Proxy Solicitation statement. It is not a report publication announcement (RPA) because it contains the full substantive content required for shareholder decision-making.
2025-03-11 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) with UNICEF. This is a specific type of material event disclosure required by stock exchange regulations in Korea for significant contracts. Since it does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-03-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.